Preclinical CRO
We are thought leaders in pharmacology and imaging.
With expertise in multiple therapeutic areas, our industry knowledgeable scientists provide seamless support for your R&D effort.
PDX models
Our process begins with the right model selection.
With our deep pharmacology and models expertise, your studies are implemented correctly from the beginning.
Molecular Imaging Preclinical Oncology
We stand beside you and your science.
With personalized attention, flexibility and responsiveness, we become an extension of your team.
Preclinical Imaging
We set the standard for industry relevant protocols.
We offer a broad array of efficient, validated pharmacology and imaging protocols to meet your needs.
Knowledge
Process
Partnership
Excellence

Molecular Imaging, Inc. is a specialty CRO combining expertise in small animal in-vivo pharmacology and imaging. Our unique pharmaco-IMAGING platform allows for enhanced decision making in your discovery and development programs. 
For over 10 years, Molecular Imaging has provided pharmacology services and pioneered the application of multi-modality imaging. We have executed over 2,500 studies, 500 of which involved imaging, to more than 150 pharmaceutical and biotechnology clients. 

Events

21st May 2014
Join us in Boston at WPC
Westin Boston Waterfront
Stop by Booth #7 to speak with us.
5th Apr 2014
Stop by the MII booth at the Annual AACR Conference
San Diego
Visit Booth 1545 to speak with us and our partner Oncotest about the exciting...
10th Feb 2014
See you at Molecular Tri-Con
Stop by the Cancer Channel at the conference to hear our VP of Oncology, Dr. W....

In the News

Spotlight

View the latest edition of Envision: The Molecular Imaging Newsletter. Learn more about our oncology services and read a word from our Director Oncology pharmaco-IMAGING, Dr. Maryland Franklin.  Click Here

 

 

Home

Preclinical Contract Research Organisation specializing in Multi-Modality Imaging studies across a wide range of Therapeutic Areas that enhance the effectiveness and efficiency of R&D decision making efforts for new drugs, biologics, devices and diagnostics.